Cargando…
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer
Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment. Bone destruction in skeletal metastases results from osteoclast-induced bone resorption. Therefore, a new approach in the therapy of bone metastases consists in using aminobisphosphonates, such as pami...
Autores principales: | Vitale, G, Fonderico, F, Martignetti, A, Caraglia, M, Ciccarelli, A, Nuzzo, V, Abbruzzese, A, Lupoli, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363684/ https://www.ncbi.nlm.nih.gov/pubmed/11401309 http://dx.doi.org/10.1054/bjoc.2001.1832 |
Ejemplares similares
-
Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
por: Dodwell, D. J., et al.
Publicado: (1990) -
Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017) -
8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor
por: Budillon, A, et al.
Publicado: (1999) -
Pamidronate Disodium for Palliative Therapy of Feline Bone-Invasive Tumors
por: Wypij, Jackie M., et al.
Publicado: (2014) -
Intravenous Pamidronate for Refractory Lymphedema
por: Beigi, A A, et al.
Publicado: (2011)